Dementia with Diabetes – Pipeline Insight, 2020
![](/report_cover/8047/dementia-with-diabetes-pipeline-insight-2020_en.gif)
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Dementia with Diabetes – Pipeline Insight, 2020,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Dementia with Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Dementia with Diabetes: Overview
Diabetes can cause several complications, such as damage to blood vessels. Diabetes is considered a risk factor for vascular dementia. This type of dementia occurs due to brain damage that is often caused by reduced or blocked blood flow to brain. Many people with diabetes have brain changes that are hallmarks of both Alzheimer's disease and vascular dementia. Some researchers think that each condition fuels the damage caused by the other.
There's a lot of research suggesting a connection between diabetes and Alzheimer's-though those connections aren't yet fully understood. Not all studies confirm the connection, but many do suggest that people with diabetes, especially type 2 diabetes, are at higher risk of eventually developing Alzheimer's dementia or other dementias. Diabetes may also increase the risk of developing mild cognitive impairment (MCI), a condition in which people experience more thinking (cognitive) and memory problems than are usually present in normal aging.
Insulin in the Brain
Sensitivity of target cells in the periphery and in the central nervous system (CNS) to insulin, a peptide hormone secreted by pancreatic ?-cells, is suppressed in type 2 diabetes. The CNS is rich with insulin receptors, most prominently in areas important for learning and memory, including the hippocampus, amygdala, parahippocampal gyrus, thalamus, and caudate-putamen.
Role of Insulin in Learning and Memory
A number of studies support insulin as an important factor in normal memory functioning. Potential mechanisms for the influence of insulin on memory include regional effects of insulin on cerebral glucose metabolism, influence on components of the long-term potentiation cascade, and modulation of acetylcholine and norepinephrine, neurotransmitters that are known to influence cognitive function.
Treatment
Currently, there are different classes of orally available pharmacological agents to treat Type II diabetes: 1) sulfonylureas, 2) meglitinides, 3) metformin (a biguanide), 4) thiazolidinediones (TZDs), 5) alpha glucosidase inhibitors, 6) dipeptidyl peptidase IV (DPP-4) inhibitors, 7) bile acid sequestrants, 8) dopamine agonists, and 9) sodium-glucose transport protein 2 (SGLT2) inhibitors. The treatment regimen for Dementia with Diabetes includes non-insulin therapy (Metformin, Thiazolidinedione, Sulfonylureas Meglitinides, Dipeptidyl peptidase-4 inhibitors and Sodium-glucose cotransporter-2 (SGLT-2)), and insulin therapy.
Dementia with Diabetes Emerging Drugs Chapters
This segment of the Dementia with Diabetes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dementia with Diabetes Emerging Drugs
Further product details are provided in the report……..
Dementia with Diabetes: Therapeutic Assessment
This segment of the report provides insights about the different Dementia with Diabetes drugs segregated based on following parameters that define the scope of the report, such as:
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
Dementia with Diabetes: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dementia with Diabetes therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dementia with Diabetes drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Dementia with Diabetes – Pipeline Insight, 2020,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Dementia with Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Dementia with Diabetes: Overview
Diabetes can cause several complications, such as damage to blood vessels. Diabetes is considered a risk factor for vascular dementia. This type of dementia occurs due to brain damage that is often caused by reduced or blocked blood flow to brain. Many people with diabetes have brain changes that are hallmarks of both Alzheimer's disease and vascular dementia. Some researchers think that each condition fuels the damage caused by the other.
There's a lot of research suggesting a connection between diabetes and Alzheimer's-though those connections aren't yet fully understood. Not all studies confirm the connection, but many do suggest that people with diabetes, especially type 2 diabetes, are at higher risk of eventually developing Alzheimer's dementia or other dementias. Diabetes may also increase the risk of developing mild cognitive impairment (MCI), a condition in which people experience more thinking (cognitive) and memory problems than are usually present in normal aging.
Insulin in the Brain
Sensitivity of target cells in the periphery and in the central nervous system (CNS) to insulin, a peptide hormone secreted by pancreatic ?-cells, is suppressed in type 2 diabetes. The CNS is rich with insulin receptors, most prominently in areas important for learning and memory, including the hippocampus, amygdala, parahippocampal gyrus, thalamus, and caudate-putamen.
Role of Insulin in Learning and Memory
A number of studies support insulin as an important factor in normal memory functioning. Potential mechanisms for the influence of insulin on memory include regional effects of insulin on cerebral glucose metabolism, influence on components of the long-term potentiation cascade, and modulation of acetylcholine and norepinephrine, neurotransmitters that are known to influence cognitive function.
Treatment
Currently, there are different classes of orally available pharmacological agents to treat Type II diabetes: 1) sulfonylureas, 2) meglitinides, 3) metformin (a biguanide), 4) thiazolidinediones (TZDs), 5) alpha glucosidase inhibitors, 6) dipeptidyl peptidase IV (DPP-4) inhibitors, 7) bile acid sequestrants, 8) dopamine agonists, and 9) sodium-glucose transport protein 2 (SGLT2) inhibitors. The treatment regimen for Dementia with Diabetes includes non-insulin therapy (Metformin, Thiazolidinedione, Sulfonylureas Meglitinides, Dipeptidyl peptidase-4 inhibitors and Sodium-glucose cotransporter-2 (SGLT-2)), and insulin therapy.
Dementia with Diabetes Emerging Drugs Chapters
This segment of the Dementia with Diabetes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dementia with Diabetes Emerging Drugs
- Azeliragon (TTP488): vTv Therapeutics
Further product details are provided in the report……..
Dementia with Diabetes: Therapeutic Assessment
This segment of the report provides insights about the different Dementia with Diabetes drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Dementia with Diabetes
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Subcutaneous
- Intravenous
- Oral
- Intramuscular
- Molecule Type
- Proteins and Peptides
- Small molecules
- Hormones
- Enzymes
- Product Type
Dementia with Diabetes: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dementia with Diabetes therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dementia with Diabetes drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Dementia with Diabetes R&D. The therapies under development are focused on novel approaches to treat/improve Dementia with Diabetes.
- Currently, several trials with anti-diabetic drugs in AD are underway and their results are expected in the next few years. Besides, further studies exploring the molecular mechanisms underlying the favorable effects of anti-diabetic drugs in the CNS could open new perspectives on future treatments.
- Dementia with Diabetes Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Dementia with Diabetes drugs?
- How many Dementia with Diabetes drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dementia with Diabetes?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dementia with Diabetes therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Dementia with Diabetes and their status?
- What are the key designations that have been granted to the emerging drugs?
- vTv Therapeutics
- Azeliragon (TTP488)
Introduction
Executive Summary
Dementia with Diabetes: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Dementia with Diabetes – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Dementia with Diabetes companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Dementia with Diabetes Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II/III)
Comparative Analysis
Azeliragon (TTP488): vTv Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Dementia with Diabetes Key Companies
Dementia with Diabetes Key Products
Dementia with Diabetes- Unmet Needs
Dementia with Diabetes- Market Drivers and Barriers
Dementia with Diabetes- Future Perspectives and Conclusion
Dementia with Diabetes Analyst Views
Dementia with Diabetes Key Companies
Appendix
Executive Summary
Dementia with Diabetes: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Dementia with Diabetes – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Dementia with Diabetes companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Dementia with Diabetes Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II/III)
Comparative Analysis
Azeliragon (TTP488): vTv Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Dementia with Diabetes Key Companies
Dementia with Diabetes Key Products
Dementia with Diabetes- Unmet Needs
Dementia with Diabetes- Market Drivers and Barriers
Dementia with Diabetes- Future Perspectives and Conclusion
Dementia with Diabetes Analyst Views
Dementia with Diabetes Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Dementia with Diabetes
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Dementia with Diabetes
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Dementia with Diabetes
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Dementia with Diabetes
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products